U.S. Health Secretary Alex Azar – Page 2

Convalescent Plasma Flunks Study in Covid-19 Patients with Severe Pneumonia

Argentina, Convalescent Plasma, COVID-19 Infections, Covid-19 Pneumonia, COVID-19 Studies, Emergency Use Authorization, FDA, Mortality, R&D, SARS-CoV-2 virus, The New England Journal of Medicine (NEJM), U.S. Health Secretary Alex Azar

A study showed the use of convalescent plasma provided no clinical benefit nor improved mortality in Covid-19 patients with pneumonia.

Pfizer files Covid-19 vaccine application to U.S. FDA

AstraZeneca, BioNTech, Business, Clinical Trials, Covid-19 Data, COVID-19 Vaccines, Emergency Use Authorization, FDA, Johnson & Johnson, Moderna, Novel Coronavirus, Pfizer, R&D, Shares, U.S. Health Secretary Alex Azar

Pfizer Inc. applied to U.S. health regulators for emergency use authorization (EUA) of the company’s Covid-19 vaccine, the first such application in a major step toward providing protection against the new coronavirus.

U.S. has plan to start Pfizer vaccine shots in December: CNBC

Antibody Drugs, Business, Clinical Trials, CNBC, COVID-19 Vaccinations, Department of Health and Human Services (HHS), Eli Lilly, Moderna, Pfizer, R&D, U.S. Health Secretary Alex Azar, United States

U.S. Health Secretary Alex Azar said if pharmaceutical company Pfizer Inc. submits interim Covid-19 vaccine to health regulators as quickly as expected, the U.S. government anticipates the beginning of vaccinating Americans in December.